berberine has been researched along with trimethyloxamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, J; Hu, J; Hu, T; Jiang, Y; Li, J; Liu, S; Shi, Y; Wang, B; Yan, W | 1 |
| Du, Y; Hong, B; Jiang, J; Jiang, Z; Li, X; Su, C; Wang, L; Yang, M; Yang, Y; Zhang, J; Zhang, X; Zhang, Y | 1 |
2 other study(ies) available for berberine and trimethyloxamine
| Article | Year |
|---|---|
Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Berberine; Cytokines; Denaturing Gradient Gel Electrophoresis; Diet, High-Fat; Gastrointestinal Microbiome; Inflammation Mediators; Liver; Male; Methylamines; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxygenases; Principal Component Analysis | 2018 |
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome.
Topics: Animals; Atherosclerosis; Berberine; Choline; Diet; Disease Models, Animal; Disease Susceptibility; Dysbiosis; Gastrointestinal Microbiome; Methylamines; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE | 2021 |